A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil- epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)

European Journal of Cancer

Volumn 50, Issue 1, 2014, Pages 23-30

  Delbaldo, C ^a   Serin, D ^b   Mousseau, M ^c   Greget, S ^d   Audhuy, B ^e   Priou, F ^f   Berdah, J F ^g   Teissier, E ^h   Laplaige, P ⁱ   Zelek, L ^j   Quinaux, E ^k   Buyse, M ^k   Piedbois, P ^l  

^a GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^b INSTITUT SAINTE CATHERINE   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d Clinique Sainte Clotilde   (France)

^e Pasteur Hospital   (France)

^f Centre Hospitalier Departemental   (France)

^g Clinique Sainte Marguerite   (France)

^h Centre Azureen de Cancerologie   (France)

ⁱ Polyclinique de Blois ^*  (France)

^j AVICENNE HOSPITAL   (France)

^k INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^l HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Adjuvant chemotherapy; Anthracycline; Breast cancer; Efficacy; Paclitaxel; Phase III

Indexed keywords

5 FLUOROURACI; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MIDDLE AGED; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADJUVANT CHEMOTHERAPY; ANTHRACYCLINE; BREAST CANCER; EFFICACY; PACLITAXEL; PHASE III;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84891634589     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.09.023     Document Type: Article

References (12)

1. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 1998 930 942
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
3. H. Roché, P. Fumoleau, and M. Spielmann et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial J Clin Oncol 24 2006 5664 5671
4. M. Martin, A. Rodriguez-Lescure, and A. Ruiz et al. Randomized phase 3 trial of Fluorouracil, epirubicin and cyclophosphaide alone or followed by paclitaxel for early breast cancer J Natl Cancer Inst 100 2008 805 814
5. I.C. Henderson, D.A. Berry, and G.D. Demetri et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
6. E.P. Mamounas, J. Bryant, and B. Lembersky et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 2005 3686 3696
7. L.S. Freedman Tables of the number of patients required in clinical trials using the log rank test Statist Med 1 1982 121 129
8. R. Peto, C. Davies, and J. Godwin et al. Early breast cancer trialists' collaborative group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 2012 432 444
9. K. Albain, W. Barlow, and F. O'Malley et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, oestrogen and/or progesterone receptor-positive breast cancer; mature outcomes an new biological correlates on phase III intergroup trial 0100 (SWOG-8814) Breast Cancer Res Treat 88 2004 37
10. D.A. Berry, C. Cirrincione, and I. Craig Henderson et al. Oestrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 2006 1658 1667
11. M. Martin, J. Mackey, and C. Vogel et al. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer Breast 16 2007 S127 S131
12. D.F. Hayes, A.D. Thor, and L.G. Dressler et al. HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 2007 1496 1506